OneSource Specialty Pharma Q4 FY26: Revenue Surges 47% QoQ as Semaglutide Engines Ignite; Reaffirms $400M FY28 Guidance

1. At a Glance

OneSource Specialty Pharma is currently the eye of the storm in the Indian CDMO (Contract Development and Manufacturing Organisation) landscape. If you are looking for a quiet, steady-state pharma utility, you are in the wrong place. This is a high-octane, high-stakes bet on the “GLP-1” (Weight loss/Diabetes) gold rush, and the numbers are finally starting to scream.

In Q4 FY26, the company reported a massive 47% sequential revenue growth, hitting ₹4,282 million. For context, the previous quarter was a graveyard of “deferred revenues” and “approval delays” that saw the company bleed a PAT loss of ₹472 million. Fast forward three months, and the narrative has shifted from “waiting for Godot” to “delivering the goods.” The launch of Semaglutide (generic Ozempic/Wegovy) in India across multiple brands has turned the EBITDA tap back on, with a 5x+ jump quarter-on-quarter to ₹919 million.

But don’t let the Q4 celebration blind you to the carnage of the full year. FY26 was a transition year, and “transition” in finance is often a polite word for “painful.” Full-year EBITDA is down 35% YoY, and the company remains in a net loss position for the year (₹738 million). The market is currently pricing in a future where OneSource becomes a global powerhouse in drug-device combinations, yet the balance sheet is groaning under a ₹1,504 crore debt pile and a massive ₹700 crore+ capex program.

The intrigue lies in the “Walk the Talk” factor. Management has doubled down on their $400 million organic revenue guidance for FY28. To hit that, they need to execute perfectly on global launches in Canada, the US, and emerging markets. One regulatory hiccup or one more “request for information” from Health Canada, and this high-flying bird could see its wings clipped.

Investors are currently staring at a company that has successfully pivoted from a complex demerger into a pure-play specialty CDMO, but the debt-to-equity and high debtor days (177 days) remain flashing red lights on the dashboard. Is the Q4 recovery the start of a multi-year bull run, or a temporary relief rally before the weight of debt and competition kicks in?

2. Introduction

OneSource Specialty Pharma Limited is not your typical neighborhood pharmacy player. Born from a series of complex demergers involving Strides Pharma Science and Steriscience, the company has emerged as a specialized, multi-modality CDMO. Its playground? High-entry-barrier segments like Biologics, Soft Gelatin Capsules, and the crown jewel—Drug-Device Combinations (DDC).

The company is led by Arun Kumar, a veteran known for his “buy-build-monetize” playbook. The strategy here is clear: capture the massive global demand for GLP-1 analogues (Semaglutide, Liraglutide, and Tirzepatide) by providing the specialized devices—pens and cartridges—that the big pharma boys need but can’t always manufacture at scale.

The recent history has been a rollercoaster. After a successful listing and fund infusion of ₹801 crore in late 2024, the company hit a wall in late 2025 due to regulatory delays in Canada. These weren’t just “paperwork” delays; they were revenue-killing events that forced a massive deleveraging of their operating margins.

However, Q4 FY26 suggests the tide is turning. With 35+ approved ANDAs in the US and a workforce that has scaled to 1,600+ professionals, the infrastructure is ready. The company is no longer just a “concept”; it is now a commercial engine supporting some of the largest generic launches in the G7 markets.

The real story, however, isn’t just about the revenue. It’s about the Biosecure Act and the global shift away from Chinese supply chains. OneSource is positioning itself as the “India-plus-one” alternative for global biotech firms. But as any seasoned auditor will tell you, a great story doesn’t pay the interest on ₹1,500 crores of debt. The execution in the next 24 months will determine if this becomes a case study in success or a cautionary tale of over-leverage.

3. Business Model – WTF Do They Even Do?

If you think OneSource just makes pills, you’ve missed the point entirely. They are a Contract Development and Manufacturing Organisation (CDMO). In plain English: Big Pharma companies bring them the “recipe” (drug substance), and OneSource provides the “kitchen” (manufacturing facilities) and the “delivery mechanism” (injectable pens/cartridges).

The business is split into four high-complexity verticals:

1. Drug-Device Combinations (DDC): This is where the magic (and the margin) is. They manufacture the auto-injectors and pens for GLP-1 drugs.
2. Biologics: Focused on mammalian and microbial fermentation. This is the future of medicine, and OneSource has 4KL of Mammalian and 1KL of Microbial capacity ready to rock.
3. Soft Gelatin Capsules: A legacy strength from the Strides demerger. They have a massive 2.4 billion unit capacity.
4. Sterile Fill-Finish: The specialized art of putting drugs into vials and syringes without any contamination.

Their model is a shift from MSAs (Manufacturing Service Agreements)—where they get paid for development—to CSAs (Commercial Supply Agreements)—where they get paid for every unit shipped. The goal is to move from being a “lab partner” to a “factory partner.”

The logic is simple: Big pharma is lazy. They don’t want to build ₹1,000 crore factories for every new drug. They outsource to OneSource, who takes the capital risk in exchange for long-term “take-or-pay” contracts. It’s a high-moat business because once a drug is filed with a specific manufacturer, changing it is a regulatory nightmare.

4. Financials Overview

The numbers for Q4 FY26 show a violent recovery. When management says “operating leverage,” this is what they mean: a small increase in revenue leads to an explosion in profit because the fixed costs (factories and scientists) are already paid for.

Note: FY25 EPS was boosted by a different asset mix post-demerger.

Management “Walk the Talk” Analysis:

In the Jan 2026 ConCall, management admitted that Q3 was a disaster because Canada approvals were delayed. They promised a recovery in Q4 led by India launches. They delivered. Revenue jumped 47% sequentially. However, look at the YoY EBITDA—it’s still down significantly. Why? Because they’ve hired 300+ new employees and scaled up costs in anticipation of the $400M FY28 target. They are currently “over-staffed” for their current revenue, which is a bet on future growth.

Are they being too optimistic by maintaining the FY28 guidance despite a shaky FY26?

5. Valuation Discussion – Fair Value Range

Calculating the value of OneSource is like trying to value a tech startup that happens to own several massive chemical factories. Traditional metrics struggle because the current earnings are depressed by massive capex and recent demerger costs.

1. P/E Method:

The trailing EPS is negative, making a standard P/E useless. However, if we look at the FY28 Guidance of $400M revenue at 40% EBITDA, we get an EBITDA of $160M (~₹1,440 Cr).

• Estimated PAT at scale: ~₹700-800 Cr.
• Applying a conservative Pharma P/E of 25x: Market Cap = ₹17,500 – ₹20,000 Cr.
• Current Market Cap: ₹21,083 Cr. (The market is already pricing in most of the FY28 success).

2. EV/EBITDA Method:

• Current EV: ₹22,490 Cr.
• Latest Quarter EBITDA (Annualised): ₹91.91 Cr x 4 = ₹367.6 Cr.
• EV/EBITDA (Current): ~61x. (Extremely expensive compared to the industry median of 30x).

3. DCF Method (Back-of-the-envelope):

• Assuming 30% Growth for 5 years, then 10% terminal growth.
• Discount Rate (WACC): 12% (reflecting high debt and sector risk).
• Estimated Fair Value: ₹1,650 – ₹1,900.

Fair Value Range: ₹1,650 – ₹2,050

Disclaimer: This fair value range is for educational purposes only and is not investment advice.

6. What’s Cooking – News, Triggers, Drama

The drama at OneSource belongs on Netflix.

The Merger That Wasn’t:

Just one day ago (May 13, 2026), the board decided to pull the plug on the Steriscience merger. They were going to buy assets in Poland and Baroda, but “stakeholders” (read: angry investors) raised concerns about valuation. The board essentially said, “Fine, we’ll do it later,” and decided to focus on their organic $400M goal. This is a rare win for minority shareholders.

The GLP-1 Gold Rush:

The company is now the CDMO partner for three generic Semaglutide approvals in G7 countries. They are supporting Dr. Reddy’s and Orbicular in Canada and the US. Every time you hear about a new weight-loss drug approval, OneSource’s factories in Bengaluru start humming louder.

The Arbitration Shadow:

There is a $136.32 million (₹1,121 Cr) claim hanging over their subsidiary, Biolexis, from Prestige Biopharma. OneSource says the claim is rubbish and is fighting it in Singapore. If they lose, it’s a massive hole in the pocket. If they win, the “legal overhang” vanishes.

7. Balance Sheet

The balance sheet is the “Reality Check” department. It’s currently heavy, bloated, and under pressure.

• Borrowings doubled in one year to ₹1,504 Cr. Someone is spending money like they’ve found an infinite glitch.
• Net Worth is stagnant, which isn’t great when you’re supposed to be “growing.”
• Total Assets at ₹8,210 Cr—this is a lot of specialized “hardware” that better start producing high-margin medicine soon, or it’s just expensive scrap metal.

8. Cash Flow – Sab Number Game Hai

Cash flow is where the truth comes to die or be reborn. OneSource is currently in a “burn” phase.

Where is the money? It’s in the ground and in the machines. A negative CFO of ₹689 Cr tells you they are building massive inventory (Semaglutide stock) and waiting for customers to pay.

Where did it go? ₹495 Cr went into buying fixed assets (CFI).

Where did it come from? Debt and share proceeds. They raised ₹1,235 Cr through financing.

Basically, the company is living on borrowed time and borrowed money, hoping the “Commercial Supply” phase kicks in before the bankers start knocking.

9. Ratios – Sexy or Stressy?

The ratios look like a medical report of a patient who just ran a marathon but has a high fever.

Why do you think the debtor days are so high? Is it the industry norm, or is OneSource being used as a credit facility by its customers?

10. P&L Breakdown – Show Me the Money

The P&L is a story of a company that is finally getting its act together after a messy divorce (demerger).

• Sales: Flat YoY at ₹1,422 Cr, but the Q4 sprint saved the year from being a total washout.
• Expenses: Jumped to ₹1,117 Cr. They are paying for a 1,600-person army but only just started the war.
• Operating Profit: ₹304 Cr. Down from ₹467 Cr last year. The “transition” tax is real.
• Other Income: (₹94 Cr). Yes, they actually lost money on “other income.” That takes talent.

The company is basically a giant engine that has been idling at a red light. Q4 was the first gear. Now we see if they can shift to fifth.

11. Peer Comparison

OneSource wants to be compared to the big boys, but it’s currently the “scrappy underdog” with a heavy backpack.

*P/E is based on annualised Q4 EPS.

Sarcastic Note: Sun Pharma and Lupin are running a marathon at Olympic speeds. OneSource is currently tying its shoelaces but telling everyone it will win the gold in 2028. The P/E of 61x makes it look like a tech stock, while the ROCE of 0.57% makes it look like a sleepy PSU.

12. Miscellaneous – Shareholding and Promoters

Promoters (30.48%): Led by Arun Kumar. He’s the guy who sold Agila to Mylan for $1.6B. He’s a deal-maker. The roast? He’s currently pledged 38.4% of his holding. Pledging is the corporate equivalent of “pawning the family jewelry” to fund a new business.

FIIs (17.50%): Big names like Amansa and Smallcap World Fund are in. They are betting on the jockey (Arun) more than the horse.

DIIs (20.61%): Motilal Oswal and Quant MF are piling in. Quant loves momentum, and OneSource is definitely moving.

Public (31.40%): Includes heavyweights like Mukul Agrawal. If the big sharks are circling, there’s usually blood (or gold) in the water.

13. Corporate Governance – Angels or Devils?

OneSource has a board that looks impressive on paper, but the governance story has some “gray” areas.

First, the Pledged Shares. 38% of the promoter’s skin in the game is tied up in debt obligations. This creates “forced sell” risks if the stock price crashes.

Second, the Related Party Transactions. Being a demerged entity of Strides, there are multiple MSAs and service agreements with sister companies. Auditors call this “complex”; investors call it a “headache.”

Third, the Merger Flip-Flop. Announcing a merger with Steriscience and then canceling it within months due to “valuation concerns” suggests either they didn’t do their homework or the pushback from institutional investors was far more brutal than expected.

However, they’ve had 210+ successful audits and zero critical observations from the USFDA lately. In pharma, the FDA is the only “God” that matters, and OneSource is currently in God’s good books.

14. Industry Roast and Macro Context

The CDMO industry is currently the “cool kid” in the pharma playground. Everyone wants to move away from China (thanks, Biosecure Act), and India is the obvious destination.

But here’s the roast: Everyone and their grandmother is starting a CDMO. From Gland Pharma to Suven to Enzene, the space is getting crowded. OneSource’s “edge” is the GLP-1 device specialty. But if the patent holders (Novo Nordisk/Eli Lilly) decide to slash prices or change the device design, the “generic” manufacturers and their CDMO partners will be left holding very expensive pens with no ink.

Macro-wise, the US generic market is a race to the bottom. If OneSource doesn’t move fast into “Value-Added” biologics, they’ll just be another factory owner fighting over pennies.

15. EduInvesting Verdict

OneSource Specialty Pharma is a high-conviction bet on Execution. The company has moved from the “Story” phase to the “Startup” phase of its new lifecycle.

Past Performance: Messy, loss-making, and dominated by demerger noise.

Future Potential: Massive. If they hit $400M in FY28 with 40% EBITDA, the current valuation will look like a bargain. If they miss, the debt will swallow them.

SWOT Analysis:

• Strengths: First-mover in G7 Semaglutide CDMO; stellar FDA track record; experienced promoter.
• Weaknesses: High debt (₹1,504 Cr); negative cash flows; high debtor days; promoter pledge.
• Opportunities: Biosecure Act tailwinds; explosion in weight-loss drug demand; scaling Biologics.
• Threats: Legal claim from Prestige Biopharma (₹1,121 Cr); intense competition; regulatory delays.

The next two quarters will be “relatively soft” as per management, but the “exit run rate” of FY27 will be the true test. This is not a company for the faint-hearted. It’s for those who believe that India can manufacture complex devices as well as it manufactures software.

Fair Value Range Disclaimer

This fair value range is for educational purposes only and is not investment advice. Investing in small/mid-cap pharma stocks involves significant risk, including loss of capital. Conduct your own due diligence before making any financial decisions.